Company Insights

CHRS customer relationships

Explore interactive graphBrowse insights index
CHRS customer relationship map

Coherus BioSciences (CHRS): customer map and commercial pivot that redefines revenue visibility

Coherus BioSciences builds and monetizes through commercial biosimilars and PD‑1 oncology products, selling finished product to wholesalers and distributors in the U.S., and selectively monetizing future receipts through asset sales and revenue‑participation transactions. Recent divestitures of UDENYCA, CIMERLI and other franchises have converted future commercial upside into near‑term cash, while supply and clinical agreements sustain an operational footprint in oncology. For investors, the company now looks more like a commercial-asset manager than a traditional growth‑stage biologics developer: proceeds from sales and revenue participation are the current cash engine, with retained programs and partner supply agreements providing optionality.

Learn more about how we surface commercial counterparties at https://nullexposure.com/.

How Coherus sells value: from wholesaler networks to revenue participation

Coherus historically sold its biosimilars through wholesalers and distributors that then service hospitals and clinics; that go‑to‑market model produced concentrated customer relationships with large pharmacy distributors. Over the past two years the company has executed a deliberate commercial contraction: asset sales (CIMERLI, UDENYCA, YUSIMRY) and a revenue‑participation sale reallocated cash generation away from recurring net product sales toward one‑time and royalty‑style receipts. These transactions changed the cash‑flow profile and reduced ongoing commercial operating scale while crystallizing value.

  • Key commercial posture: concentrated, U.S.‑centric revenue; significant use of monetization transactions (asset sales and revenue participation).
  • Distribution model: sells to wholesalers/distributors who resell to hospitals and clinics under contract.
  • Revenue profile: mix of direct product revenue and structured sale/royalty receipts following divestitures.

If you want a concise counterparty map for diligence and risk assessment, start at https://nullexposure.com/.

Customer and partner relationships — who matters now

Below are the counterparties surfaced in public filings and press coverage; each entry contains a plain‑English take and the supporting source.

AmeriSourceBergen Corp.

AmeriSourceBergen is listed as a fiscal‑year customer in Coherus’ FY2024 10‑K, reflecting wholesaler/distributor receipts that feed hospital and clinic channels. According to Coherus’ FY2024 Form 10‑K, AmeriSourceBergen is reported in the company’s customer list and associated customer concentration disclosures (FY2024 10‑K).

McKesson

McKesson is a reported customer in FY2024, appearing in Coherus’ customer concentration notes as a distributor that purchases product for resale to clinical settings (FY2024 Form 10‑K).

Cardinal

Cardinal Health is likewise named among Coherus’ large distributor customers, consistent with the company’s standard commercial model of selling through national wholesalers (FY2024 Form 10‑K).

Intas Pharmaceuticals / Intas Pharmaceuticals Ltd.

Intas acquired the UDENYCA franchise from Coherus in a transaction disclosed as valued up to $558.4 million, and the deal structure included a significant upfront payment component; Coherus completed the divestiture pursuant to the December 2, 2024 asset purchase agreement and closed in 2025 (GlobeNewswire, Apr 14, 2025; industry coverage noted the upfront and milestone structure, FierceBiotech).

Accord BioPharma, Inc.

Accord — Intas’ U.S. specialty unit — assumed responsibility for the UDENYCA franchise in the U.S., continuing commercial supply and distribution of the product domestically after the transaction closed (PR Newswire announcement and Contract Pharma coverage, April 2025).

Sandoz Group / Sandoz

Sandoz acquired Coherus’ CIMERLI ophthalmology franchise for an upfront payment (reported at $170 million), a strategic divestiture that transferred an interchangeable ranibizumab biosimilar business and its U.S. commercial rights to Sandoz (PharmExec and industry reports, 2025/2026 coverage).

HKF

Coherus sold its YUSIMRY franchise to HKF for a reported $40 million, a smaller asset sale consistent with the company’s program of portfolio pruning and cash generation (TradingView summary of Coherus’ SEC filing).

Apotex

Coherus entered an exclusive license agreement with Apotex for Canadian commercialization of certain products, signaling a territory‑specific commercialization partnership outside Coherus’ U.S. focus (Coherus 10‑K summary reported on TradingView).

Coduet Royalty Holdings, LLC

Coduet purchased revenue participation rights tied to LOQTORZI (and related revenue streams) under a Revenue Purchase and Sale Agreement commenced May 8, 2024, converting a portion of future product receipts into immediate cash for Coherus (Coherus Q1 2025 financial results and business update, GlobeNewswire, May 12, 2025).

INOVIO (INO)

Coherus agreed to supply LOQTORZI for a Phase 3 trial conducted by Inovio, committing clinical supply to support combination development and indicating an active clinical‑supply partnership role (PR Newswire clinical collaboration announcement, 2025/2026).

Janssen Research & Development, LLC

Coherus Oncology announced a clinical supply agreement with Janssen Research & Development, reinforcing Coherus’ role as a supplier in oncology clinical programs (MarketScreener notice, Feb 4, 2026).

What the constraints tell investors about the operating model

Coherus’ public disclosures and transaction language provide company‑level signals that shape commercial risk and value realization:

  • Contracting posture: the company uses a mix of traditional product sales and structured monetization — including a usage‑based revenue participation sale — to convert future royalties into current cash flows; evidence shows explicit percentage‑of‑sales revenue payments in those agreements.
  • Counterparty profile: interactions are primarily with large enterprise buyers and wholesalers — integrated delivery networks and national distributors are core counterparties — so commercial exposure is concentrated among a few large accounts.
  • Geography and concentration: all net product revenue is generated in the United States, concentrating regulatory, reimbursement and market access risk in a single market.
  • Relationship roles and criticality: Coherus acts as both seller to distributors and seller of commercial assets/rights; distributors are critical for day‑to‑day revenue while asset buyers provide liquidity and de‑risking of commercial programs.
  • Product segmentation: retained exposure focuses on core products and distribution agreements (UDENYCA and LOQTORZI were core franchises; divestitures change the mix but do not eliminate distribution relationships).

These are company‑level constraints and signals derived from the firm’s filings and transaction descriptions, not attributions tied to any single counterparty unless explicitly named in the excerpts.

Explore detailed counterparty maps and transaction summaries at https://nullexposure.com/ for deal‑level diligence and ongoing monitoring.

Investment implications and what to watch next

Coherus now trades with a commercial‑asset profile: near‑term cash from divestitures reduces funding pressure but also caps upside from direct product sales. The business depends on orderly handoffs to acquirers (Intas/Accord, Sandoz, HKF) and on continued supply and clinical deals (Inovio, Janssen) to preserve optionality in oncology. Key monitoring points for investors: realized payments from divestitures, actual ongoing distributor receipts via AmeriSourceBergen / McKesson / Cardinal, and any re‑acceleration of product development or licensing activity.

For access to structured counterparty intelligence and to track future asset transactions, visit https://nullexposure.com/.

Bottom line: Coherus has converted commercial scale into near‑term liquidity while retaining targeted clinical and supply relationships; that repositioning lowers growth runway risk but also reduces the company’s exposure to high‑growth, high‑variance commercial upside.